Roche makes a platform play, betting $190M in cash on Arrakis’ long-haul plans to drug RNA
Every biotech startup sets out at its own idea of a deliberate pace. And they often fall into 2 separate styles.
There are the sprinters who leap straight into a slate of deals, looking to align themselves with the kind of blue chip partners that help validate their place in the development pipeline.
And then there are the marathon, long-haul biotechs like Arrakis, which take a more measured approach.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,300+ biopharma pros reading Endpoints daily — and it's free.